Overview

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Status:
Not yet recruiting
Trial end date:
2025-12-28
Target enrollment:
Participant gender:
Summary
A Phase IIIb, Single-Arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Polycythemia Vera (PV)
Phase:
Phase 3
Details
Lead Sponsor:
PharmaEssentia